FTSE MIB
33.308,77 -366,33 (-1,09%) Dow Jones
39.150,33 +15,53 (+0,04%) Nasdaq
17.689,36 -32,24 (-0,18%) Nikkei 225
38.596,47 -36,53 (-0,09%) Petrolio
80,59 -0,70 (-0,86%) Bitcoin EUR
59.927,46 -200,25 (-0,33%)
Alvotech (ALVOW)
| Chiusura precedente | 3,1000 |
| Aperto | 4,1000 |
| Denaro | 0,0000 x 0 |
| Domanda | 0,0000 x 0 |
| Min-Max giorno | 3,4700 - 3,4700 |
| Intervallo di 52 settimane | 3,4700 - 3,4700 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (mensile su 5 anni) | -0,05 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAlvotech Provides Update on Status of U.S. Biologics License Application for AVT04
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT04, a biosimilar candidate to Stelara® (ustekinumab). As expected, the CRL noted that certain deficiencies, which were conveyed following the FDA’s inspection of the company’s Reykjavik fac
- GlobeNewswire
Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland
Alvotech (Nasdaq: ALVO) and Íslandsbanki hf. (“Islandsbanki”) have entered into a market making agreement. According to the market making agreement, Islandsbanki places bids and offers for ALVO shares trading on the Nasdaq Iceland Main Market (the “Exchange”) for a minimum amount with a fixed spread between the bid and offer price. Islandsbanki will post bids and offers on the exchange amounting to at least ISK 8 million at market value at any given time at a price determined by Islandsbanki, wh
- GlobeNewswire
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
REYKJAVIK, Iceland and PISCATAWAY, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company, today announced that they have entered into an exclusive licensing agreement for AVT23 (also called ADL018), a proposed biosimilar to Xolair® (omalizumab), which is currently in clinical developm
